Omnicell (NASDAQ:OMCL) Downgraded by StockNews.com to Hold

StockNews.com lowered shares of Omnicell (NASDAQ:OMCL) from a buy rating to a hold rating in a research report released on Wednesday morning.

Other equities analysts also recently issued reports about the company. Barclays upped their price target on Omnicell from $39.00 to $58.00 and gave the company an “equal weight” rating in a report on Thursday, October 31st. Wells Fargo & Company upped their price target on Omnicell from $30.00 to $41.00 and gave the company an “equal weight” rating in a report on Monday, October 14th. Bank of America reaffirmed a “neutral” rating and issued a $57.00 price target (up from $44.00) on shares of Omnicell in a report on Thursday, October 31st. Craig Hallum upped their price target on Omnicell from $45.00 to $64.00 and gave the company a “buy” rating in a report on Thursday, October 31st. Finally, JPMorgan Chase & Co. upped their price target on Omnicell from $37.00 to $44.00 and gave the company a “neutral” rating in a report on Thursday, November 21st. Five analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $52.00.

Omnicell Stock Performance

Shares of Omnicell stock opened at $48.46 on Wednesday. Omnicell has a one year low of $25.12 and a one year high of $55.74. The company has a market cap of $2.24 billion, a PE ratio of -124.25, a P/E/G ratio of 34.92 and a beta of 0.81. The business has a 50-day simple moving average of $44.41 and a 200-day simple moving average of $37.75.

Institutional Investors Weigh In On Omnicell

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Nisa Investment Advisors LLC raised its stake in shares of Omnicell by 248.8% during the second quarter. Nisa Investment Advisors LLC now owns 1,402 shares of the company’s stock worth $38,000 after purchasing an additional 1,000 shares during the last quarter. GAMMA Investing LLC raised its stake in shares of Omnicell by 78.4% during the third quarter. GAMMA Investing LLC now owns 1,258 shares of the company’s stock worth $55,000 after purchasing an additional 553 shares during the last quarter. CWM LLC raised its stake in shares of Omnicell by 68.2% during the second quarter. CWM LLC now owns 3,048 shares of the company’s stock worth $83,000 after purchasing an additional 1,236 shares during the last quarter. 1620 Investment Advisors Inc. raised its stake in shares of Omnicell by 230.1% during the third quarter. 1620 Investment Advisors Inc. now owns 2,212 shares of the company’s stock worth $96,000 after purchasing an additional 1,542 shares during the last quarter. Finally, Headlands Technologies LLC purchased a new stake in shares of Omnicell during the second quarter worth approximately $104,000. Hedge funds and other institutional investors own 97.70% of the company’s stock.

Omnicell Company Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.